Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study
暂无分享,去创建一个
V. de Lédinghen | D. Neau | P. Morlat | F. Dabis | F. Raffi | P. Sogni | G. Pialoux | K. Lacombe | D. Vittecoq | C. Goujard | M. Valantin | I. Poizot-Martin | L. Alric | É. Rosenthal | D. Salmon | L. Piroth | D. Zucman | O. Bouchaud | A. Simon | L. Esterle | S. Dominguez | C. Lascoux-Combe | C. Duvivier | L. Wittkop | P. Miailhes | F. Bani-Sadr | H. Aumaître | D. Garipuy | Sarah Shili-Masmoudi | Anne Gervais-Hasenknoff
[1] D. Neau,et al. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. , 2017, Journal of hepatology.
[2] A. Mocroft,et al. Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] D. Neau,et al. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] P. Easterbrook,et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.
[5] P. Bacchetti,et al. Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV , 2016, AIDS.
[6] P. Phanuphak,et al. Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival , 2016, PloS one.
[7] R. Weber,et al. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy , 2015, PloS one.
[8] Anrs Co Hepavih Cohort. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients , 2015, AIDS.
[9] R. Weber,et al. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. , 2015, Journal of hepatology.
[10] A. Localio,et al. Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients , 2015, Open forum infectious diseases.
[11] M. Esteban,et al. Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response , 2015, Digestive Diseases and Sciences.
[12] A. Mocroft,et al. Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals , 2015, AIDS.
[13] Brad J. Wood,et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. , 2015, JAMA.
[14] J. Rockstroh,et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study , 2015, The Lancet.
[15] E. Moodie,et al. Mortality in HIV–hepatitis C co-infected patients in Canada compared to the general Canadian population (2003–2013) , 2014, AIDS.
[16] O. Kirk,et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration , 2014, The Lancet.
[17] M. Crespo,et al. Effects of Sustained Viral Response in Patients With HIV and Chronic Hepatitis C and Nonadvanced Liver Fibrosis , 2014, Journal of acquired immune deficiency syndromes.
[18] P. Morlat,et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000 , 2014, AIDS.
[19] B. Clotet,et al. Progression of liver fibrosis in HIV/hepatitis C virus‐coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline , 2014, HIV medicine.
[20] J. Macías,et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] B. Clotet,et al. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era. , 2012, AIDS research and human retroviruses.
[22] J. Mallolas,et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Richard D Moore,et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. , 2012, JAMA.
[24] D. Neau,et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010 , 2010, BMC infectious diseases.
[25] Dimitris Rizopoulos,et al. JM: An R package for the joint modelling of longitudinal and time-to-event data , 2010 .
[26] Michael J Silverberg,et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.
[27] J. Macías,et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus , 2009, Hepatology.
[28] C. Tural,et al. Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus , 2009, Hepatology.
[29] A. Butt,et al. Effect of hepatitis C virus and its treatment on survival , 2009, Hepatology.
[30] Cécile Proust-Lima,et al. Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. , 2009, Biostatistics.
[31] Richard D Moore,et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults , 2007, AIDS.
[32] M. Ziol,et al. Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients , 2006, Journal of acquired immune deficiency syndromes.
[33] Paul Zimmet,et al. The metabolic syndrome—a new worldwide definition , 2005, The Lancet.
[34] G. Lüchters,et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection , 2003, The Lancet.
[35] A. Mocroft,et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.
[36] T. Heeren,et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] M. Battegay,et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.